Clinical drug development has a 90% failure rate – a disheartening reality for drug development scientists, pharmaceutical companies and patients alike.
Safety is a major contributing factor to this high failure rate. Many drugs progress through preclinical stages of development, only to fail when their safety is assessed in human subjects. This process costs millions of dollars and shatters hope.
While in vitro tests and animal models can give some indication of potential safety issues, they do not always translate well to humans. Ignota Labs is tackling this challenge.
The start-up company deploys a variety of different data-driven techniques to address the different components of drug safety. Its state-of-the-art in silico models can identify the root causes of toxicity – giving scientists the information they need to improve a drug’s safety profile.
At the European Laboratory Research and Innovation Group (ELRIG)’s Research and Innovation 2024 event, Technology Networks sat down with Ignota Labs’ CEO Sam Windsor to learn about the company’s proprietary platform, SAFEPATH, and the impact AI is having on drug discovery, development and commercialisation.
Read more:
‘Using Explainable AI To Ensure Drug Discovery Safety,’ can be read in full at Technology Networks.
Published: 26 April 2024 by Technology Networks
